

Somatic symptoms in patients with chronic kidney disease

Submission date 21/12/2021	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 18/02/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 18/12/2025	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Patients with chronic kidney disease (CKD) report burdensome persistent somatic symptoms (PSS) in the early stages of renal dysfunction, long before requiring renal replacement therapy. Somatic symptom burden in CKD is an important predictor of health-related quality of life, disease progression, and also mortality. Their underlying aetiology in CKD remains unclear. The aim of this study is to improve the understanding on how PSS in CKD develop and maintain over time. It also aims to investigate biomedical, treatment-related and psychosocial predictors for the development of persistent somatic symptom burden in CKD.

The SOMA.CK study is part of the research unit RU5211 Persistent SOMatic Symptoms ACROSS Diseases (SOMACROSS P3), funded by the German Research Foundation (DFG). SOMACROSS aims to identify generic and disease-specific risk factors and aetiological mechanisms of symptom persistence across a range of medical diseases, and thereby create a foundation for evidence-based interventions for PSS.

Who can participate?

Adults from the age of 18 years with a diagnosis of chronic kidney disease (CKD) stages 2-4.

What does the study involve?

The study investigates how somatic symptoms in CKD develop and evolve over time. We will investigate the role of biomedical and psychosocial factors in predicting CKD-specific symptom burden in n = 330 patients with CKD. To this end, an observational cohort study with assessments at baseline, 6 and 12 months will be conducted. An embedded experimental study as well as a qualitative study with newly diagnosed patients will further be conducted. The experimental study will compare individuals reporting high habitual symptoms with individuals reporting low symptom levels in order to test if symptom perception is influenced by general symptom burden, negative affectivity, emotion regulation deficits and disease severity. The qualitative study will explore individual mechanisms of symptom development and symptom perception after receiving a CKD diagnosis. A healthy control group will explore symptom perception between groups.

What are the possible benefits and risks of participating?

The study will investigate predictors of somatic symptom persistence in patients with chronic kidney disease, and will not influence patients' regular medical treatment. Patients will receive their medical care as usual and there are no disadvantages for participants compared to non-participants. Results will expand our knowledge of the underlying causes of CKD and increase our understanding of the predictive role of risk factors. The study results will be the basis for future treatment and intervention possibilities that aim to improve patients' quality of life.

Where is the study run from?

The study is being conducted by the III. Medicine Clinic and Policlinic and Clinic of Psychosomatic Medicine and Psychotherapy at the University Medical Centre Hamburg-Eppendorf, Germany and the Medical School Hamburg, Germany.

When is the study starting and how long is it expected to run for?

January 2021 to December 2025

Who is funding the study?

Deutsche Forschungsgemeinschaft, DFG (German Research Foundation, Germany)

Who is the main contact?

Prof. Dr. Meike Shedden Mora, meike.shedden-mora@medicalschooll-hamburg.de

Prof. Dr. Tobias B. Huber, direktionsassistentz-3.med@uke.de

Contact information

Type(s)

Scientific

Contact name

Prof Meike Shedden Mora

ORCID ID

<https://orcid.org/0000-0003-2023-3824>

Contact details

Am Kaiserkai 1

Hamburg

Germany

20457

+49 (0) 40-361-226 49309

meike.shedden-mora@medicalschooll-hamburg.de

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

DFG SH 857/3-1 / HU 1016/13-1

Study information

Scientific Title

Predictors of somatic symptom persistence in patients with chronic kidney disease

Acronym

SOMA.CK

Study objectives

Hypothesis 1: Somatic symptom burden at 12 months in CKD can be predicted as a function of biomedical factors, treatment-related factors, psychosocial factors and their interplay.

Hypothesis 1 is broken down into three testable partial hypotheses and an exploratory research question:

Hypothesis 1a: Biomedical factors, namely renal function, comorbidity, altered DNA methylation in an epigenome-wide association study, and elevated suPAR levels, predict somatic symptom burden at 12 months.

Hypothesis 1b: Treatment-related factors, namely concurrent treatments and side-effects, predict somatic symptom burden at 12 months.

Hypothesis 1c: Psychosocial factors, specifically cognitive-perceptual variables in terms of somatosensory amplification, illness perceptions, symptom and treatment expectations, affective factors in terms of depression, (health) anxiety, and behavioural factors in terms of physical inactivity, predict somatic symptom burden at 12 months.

Hypothesis 1d: exploratory: Biopsychosocial risk factors interact in the development and maintenance of PSS in CKD.

Hypothesis 2a: Distinct symptom trajectories over a 12-months course can be predicted by biopsychosocial variables.

Hypothesis 2b: Changes in symptoms over time are predicted by biopsychosocial variables.

Hypothesis 3a: Inducing negative affect increases symptom perception in patients with CKD, particularly in patients with high baseline symptom burden, high trait negative affectivity, and deficits in emotion regulation.

Hypothesis 3b: The effect is moderated by disease severity, i.e., less pronounced symptom reporting after negative affect induction is expected in patients with high disease severity.

Hypothesis 3c: Higher symptom reporting after negative affect induction predicts greater symptom burden at 12 months.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 25/01/2021, Ethics Committee of the Hamburg Medical Association (Ethik-Kommission der Ärztekammer Hamburg, Weidestraße 122b, 22083 Hamburg, Germany; +49 (0) 40 202299-240; ethik@aekhh.de), ref. 2020-10195-BO-ff

Study design

Observational prospective cohort study mixed-methods design

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Chronic kidney disease (CKD) stages 2-4

Interventions

Current interventions as of 18/12/2025:

An observational mixed methods cohort study will be conducted in order to develop a multivariate prognostic prediction model for CKD-specific symptom burden. Using a mixed-methods approach, mechanisms of symptom perception and development of CKD in a subgroup with newly diagnosed patients will be examined.

Prospective cohort study:

A mixed methods cohort study with assessments at baseline, 6, and 12 months will explore multivariate predictors of PSS in 330 patients with CKD stages 2-4. The primary outcome will be CKD-specific somatic symptom burden. Secondary outcomes include CKD-specific quality of life, general somatic symptom burden, and functioning. Predictors based on the adapted biopsychosocial working model of RU SOMACROSS include relevant biomedical (including epigenetic mechanisms and the biomarker suPAR), treatment-related (e.g., side effects), and psychosocial variables (e.g., expectations). Patient data will be collected through self-report questionnaires, semi-structured interviews, as well as blood, stool and urine samples. Longitudinal structural equation models, latent class growth and cross-lagged panel analyses will be used.

Experimental study:

The influence of inducing negative affect on symptom perception will be examined using an affective picture paradigm. Also, it will be tested if symptom perception is moderated by baseline symptom burden, negative affectivity, emotion regulation and disease severity.

Qualitative study:

Qualitative interviews will be conducted in a subsample of patients newly diagnosed with CKD stages 2-4 in order to complement the quantitative data. Patients will undergo semi-structured interviews at baseline, 6 and 12 months. Interview questions will assess patients' symptom development, expectations of symptoms and treatment, as well as their own coping abilities.

In addition to the patient group, a healthy control group started recruiting for the experimental study in May 2023. The target number for this group will also be 100 participants. This is done to compare symptom perception after negative affect induction in healthy and physically ill individuals. Before taking part in the experiment and watching the three picture series of the IAPS, the controls are asked to fill in the following questionnaires: PHQ-15, PANAS trait, ERQ, SSAS, CSQ-CAT, and TAS-20.

Previous interventions as of 25/09/2023:

An observational mixed methods cohort study will be conducted in order to develop a

multivariate prognostic prediction model for CKD-specific symptom burden. Using a mixed-methods approach, mechanisms of symptom perception and development of CKD in a subgroup with newly diagnosed patients will be examined.

Prospective cohort study:

A mixed methods cohort study with assessments at baseline, 6, and 12 months will explore multivariate predictors of PSS in 330 patients with CKD stages 2-4. The primary outcome will be CKD-specific somatic symptom burden. Secondary outcomes include CKD-specific quality of life, general somatic symptom burden, and functioning. Predictors based on the adapted biopsychosocial working model of RU SOMACROSS include relevant biomedical (including epigenetic mechanisms and the biomarker suPAR), treatment-related (e.g., side effects), and psychosocial variables (e.g., expectations). Patient data will be collected through self-report questionnaires, semi-structured interviews, as well as blood, stool and urine samples. Longitudinal structural equation models, latent class growth and cross-lagged panel analyses will be used.

Experimental study:

In an experimental study in a subgroup of patients newly diagnosed with CKD, the influence of inducing negative affect on symptom perception will be examined using an affective picture paradigm. Also, it will be tested if symptom perception is moderated by baseline symptom burden, negative affectivity, emotion regulation and disease severity.

Qualitative study:

Qualitative interviews will be conducted in a subsample of patients newly diagnosed with CKD stages 2-4 in order to complement the quantitative data. Patients will undergo semi-structured interviews at baseline, 6 and 12 months. Interview questions will assess patients' symptom development, expectations of symptoms and treatment, as well as their own coping abilities.

In addition to the patient group, a healthy control group started recruiting for the experimental study in May 2023. The target number for this group will also be 100 participants. This is done to compare symptom perception after negative affect induction in healthy and physically ill individuals. Before taking part in the experiment and watching the three picture series of the IAPS, the controls are asked to fill in the following questionnaires: PHQ-15, PANAS trait, ERQ, SSAS, CSQ-CAT, and TAS-20.

Previous interventions:

An observational mixed methods cohort study will be conducted in order to develop a multivariate prognostic prediction model for CKD-specific symptom burden. Using a mixed-methods approach, mechanisms of symptom perception and development of CKD in a subgroup with newly diagnosed patients will be examined.

Prospective cohort study:

A mixed methods cohort study with assessments at baseline, 6, and 12 months will explore multivariate predictors of PSS in 330 patients with CKD stages 2-4. The primary outcome will be CKD-specific somatic symptom burden. Secondary outcomes include CKD-specific quality of life, general somatic symptom burden, and functioning. Predictors based on the adapted biopsychosocial working model of RU SOMACROSS include relevant biomedical (including epigenetic mechanisms and the biomarker suPAR), treatment-related (e.g., side effects), and psychosocial variables (e.g., expectations). Patient data will be collected through self-report

questionnaires, semi-structured interviews, as well as blood, stool and urine samples. Longitudinal structural equation models, latent class growth and cross-lagged panel analyses will be used.

Experimental study:

In an experimental study in a subgroup of patients newly diagnosed with CKD, the influence of inducing negative affect on symptom perception will be examined using an affective picture paradigm. Also, it will be tested if symptom perception is moderated by baseline symptom burden, negative affectivity, emotion regulation and disease severity.

Qualitative study:

Qualitative interviews will be conducted in a subsample of patients newly diagnosed with CKD stages 2-4 in order to complement the quantitative data. Patients will undergo semi-structured interviews at baseline, 6 and 12 months. Interview questions will assess patients' symptom development, expectations of symptoms and treatment, as well as their own coping abilities.

Intervention Type

Mixed

Primary outcome(s)

CKD-specific somatic symptom burden will be assessed with the CKD Symptom Burden Index (CKD-SBI) at baseline, after 6 and after 12 months.

Key secondary outcome(s)

1. CKD-related quality of life will be measured using the Kidney Disease Quality of Life 36-Item Short-Form Survey (KDQOL-36) which includes the general health-related quality of life scale SF-12 at baseline, 6 months, and 12 months.
2. General somatic symptom burden in CKD will be measured using the Patient Health Questionnaire-15 (PHQ-15) at baseline, 6 months, and 12 months.
3. Symptom intensity and interference measured using a Numeric Rating Scale (NRS) at baseline, 6 months, and 12 months.
4. Symptom-related disability measured using the Pain Disability Index (PDI) at baseline, 6 months, and 12 months.
5. General quality of life measured using the above-mentioned SF-12 at baseline, 6 months, and 12 months.
6. Disease-related variables, i.e. CKD cause, duration and severity as well as current and prior renal and comorbid illnesses measured using the Cumulative Illness Rating Scale (CIRS), core serum and urine laboratory parameters (glomerular filtration rate), venous, blood gas analysis, blood cell count, serum albumin, and cystatin c. Medication, allergies, pulse, blood pressure, respiratory rate, saturation, abdominal circumference, genetic predisposition, first diagnosis of CKD and first symptoms are measured asking the patients directly or taking missing information out of the patients' physician's letter.
7. Epigenetic variables, namely DNA methylation and histone modification.
8. Urokinase-type plasminogen activator receptor (suPAR) levels in the plasma measured with the suPARnostic ELISA kit (IBL international).
9. Concurrent treatments, assessed from the patients' physicians.
10. Subjective side effects measured using a Numeric Rating Scale (NRS) at baseline, 6 months, and 12 months.
11. Adherence of treatment measured using the Medication Adherence Rating Scale (MARS-D) at baseline, 6 months, and 12 months.
12. Somatosensory amplification measured using the Somatosensory Amplification Scale (SSAS)

at baseline, 6 months, and 12 months.

13. Illness perceptions measured using the Brief Illness Perception Questionnaire (B-IPAQ) at baseline, 6 months, and 12 months.

14. Catastrophizing measured using the Coping Strategies Questionnaire – Catastrophizing Subscale (CSQ-CAT) at baseline, 6 months, and 12 months.

15. Expectations of symptom severity, symptom coping treatment measured using a Numeric Rating Scale (NRS) and the Treatment Expectation Questionnaire (TEX-Q) at baseline, 6 months, and 12 months.

16. Perceived stress measured using the Perceived Stress Scale (PSS-10) at baseline, 6 months, and 12 months.

17. Depression measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline, 6 months, and 12 months.

18. Anxiety measured using the Generalized Anxiety Disorder-7 (GAD-7) at baseline, 6 months, and 12 months.

19. Health anxiety and illness behaviour measured using the Somatic Symptom Disorder – B Criteria Scale (SSD-12) at baseline, 6 months, and 12 months.

20. Physical inactivity measured using the International Physical Activity Questionnaire (IPAQ-SF) at baseline, 6 months, and 12 months.

Completion date

31/12/2025

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 27/09/2023:

Inclusion criteria for the patient group:

1. Clinical diagnosis of CKD stages 2-4
2. Newly diagnosed with CKD
3. Age ≥ 18 years
4. Sufficient oral and written German language proficiency
5. Provision of written consent

Inclusion criteria for the healthy control group:

1. To be at least 18 years old (equivalent to the patient group)
2. Sufficient knowledge of the German language

1. Clinical diagnosis of CKD stages 2-4
2. Newly diagnosed with CKD
3. Age ≥ 18 years
4. Sufficient oral and written German language proficiency
5. Provision of written consent

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

99 years

Sex

All

Total final enrolment

222

Key exclusion criteria

Current participant exclusion criteria as of 27/09/2023:

Exclusion criteria for the patient group:

1. Acute severe somatic or psychiatric disease
2. Florid psychosis
3. Substance abuse disorder
4. Acute suicidality
5. Cognitive impairment
6. Planned dialysis within the next 6 months
7. Current dialysis
8. Dialysis in history longer than 3 months
9. Kidney transplantation
10. Life expectancy shorter than 6 months

Exclusion criteria for the healthy control group:

1. Existence of a chronic kidney disease
2. Cognitive impairment (equivalent to the patient group)
3. Diagnosis of psychosis, schizophrenia etc. (equivalent to the patient group)
4. Drug addiction (also equivalent to the patient group)
5. Acute suicidality

Previous participant exclusion criteria:

1. Acute severe somatic or psychiatric disease
2. Florid psychosis
3. Substance abuse disorder
4. Acute suicidality
5. Cognitive impairment
6. Planned dialysis within the next 6 months
7. Current dialysis
8. Dialysis in history longer than 3 months
9. Kidney transplantation
10. Life expectancy shorter than 6 months

Date of first enrolment

12/05/2022

Date of final enrolment

28/02/2024

Locations

Countries of recruitment

Germany

Study participating centre

University Medical Centre Hamburg-Eppendorf

Department of Psychosomatic Medicine and Psychotherapy

Martinistraße 52

Hamburg

Germany

20246

Study participating centre

Medical School Hamburg

Department of Psychology

Am Kaiserkai 1

Hamburg

Germany

20457

Study participating centre

Diaverum Alter Teichweg

Alter Teichweg 59-61

Hamburg

Germany

22049

Study participating centre

Diaverum Schlankreye

Schlankreye 38

Hamburg

Germany

20144

Study participating centre

Nephrocare Hamburg-Süderelbe GmbH

Schwarzenbergstraße 29

Hamburg

Germany

21073

Study participating centre
Nephrocare Hamburg-Altona GmbH
Mörkenstraße 47
Hamburg
Germany
22767

Study participating centre
Nephrocare Hamburg-Barmbek GmbH
Hebebrandstraße 6
Hamburg
Germany
22297

Study participating centre
MVZ gGmbH der PHV Hamburg-Langenhorn
Ochsenweberstraße 12
Hamburg
Germany
22419

Sponsor information

Organisation
University Medical Center Hamburg-Eppendorf

ROR
<https://ror.org/01zgy1s35>

Organisation
Medical School Hamburg

ROR
<https://ror.org/006thab72>

Funder(s)

Funder type

Research organisation

Funder Name

Deutsche Forschungsgemeinschaft

Alternative Name(s)

German Research Association, German Research Foundation, Deutsche Forschungsgemeinschaft (DFG), DFG

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Germany

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be stored in a publicly available repository (e.g., DRYAD Digital Repository; <https://datadryad.org/stash>). The study protocol and statistical analysis plan will be available at the ISRCTN registry. Individual participant data that underlie the reported results in a published article will be shared after de-identification beginning 3 months and ending 5 years following article publication. Data can be shared with researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals should be directed to Prof. Dr. Meike Shedden Mora (meike.shedden-mora@medicalschooll-hamburg.de). To gain access, data requestors will need to sign a data access agreement. Informed consent from participants was obtained.

IPD sharing plan summary

Stored in publicly available repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		17/11/2022	18/11/2022	Yes	No
Participant information sheet		22/12/2021	22/12/2021	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes